Core Viewpoint - Guizhou Xintian Pharmaceutical Co., Ltd. has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its health food production and sales capabilities [2] Company Overview - Guizhou Xintian Pharmaceutical was founded on August 11, 1995, with a registered capital of 2,441.03806 million RMB [2] - The company specializes in the research, production, and sales of traditional Chinese medicine [2] - The current chairman is Dong Dalun, and the company employs 1,682 people [2] Business Strategy - The new subsidiary will focus on health food production, food sales, and health consulting services [2] - The investment aligns with the company's strategic development plan and aims to diversify its product matrix and improve operational scale and profitability [2] Financial Performance - Projected revenues for 2024 and Q2 2025 are 858 million RMB, 193 million RMB, and 358 million RMB, with year-on-year changes of -10.11%, 8.93%, and -18.88% respectively [3] - The net profit attributable to the parent company for the same periods is projected to be 52.3229 million RMB, 4.1875 million RMB, and 5.7661 million RMB, with year-on-year declines of -35.30%, -73.11%, and -80.99% respectively [3] - The company's asset-liability ratios for the same periods are 38.75%, 37.48%, and 37.03% [3] Risk Factors - The company has 31 internal risk alerts and 38,039 external risk alerts, indicating a significant level of risk exposure [3]

Core Viewpoint - The company has established a wholly-owned subsidiary, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd., with an investment of 10 million RMB to enhance its product matrix and overall profitability [1] Group 1: Investment Details - The investment amount is 10 million RMB, aimed at promoting the research and development of health food and its transformation into products [1] - The registered capital of Zhongdao Health is exactly 10 million RMB, with Wei Maochen as the legal representative [1] - The establishment date of the subsidiary is September 1, 2025, and it has received a business license from the Market Supervision Administration of Wudang District, Guiyang City [1] Group 2: Business Scope - The business scope of the new subsidiary includes the production of health food, special medical purpose formula food, infant formula food, food additives, dairy products, beverages, and food sales [1] - This diversification aims to enhance the company's overall profitability and risk resistance [1] - The investment aligns with the company's strategic goal of becoming a comprehensive pharmaceutical enterprise [1]